Loading stock data…
SLS
$7.68-0.30 (-3.76%)
After Hours$7.68+0.00 (+0.00%)· Last close Jun 9
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SELLAS Life Sciences Group, Inc. in the Healthcare sector is trading at $7.68 with a market capitalization of $1.6B. Wall Street consensus targets $10.00 (2 analysts), implying a +30.2% move over the next 12 months. The stock is currently 19% below its 52-week high of $9.51, remaining 107.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +30.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.68
Potential Downside
0%
Whystock Fair Value$7.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a p...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.61B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.42%
Volume
Today's trading volume
6.84M
Recent News
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute
Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers
Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.
Jim Cramer on SELLAS: “It’s a Great Spec”
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated: Oh, this life science company that is, look, okay, so this is […]
SELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer Endorsement
In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and prior Phase 2 results while the Phase 3 REGAL trial of GPS in AML moved to within two events of a topline readout. Investor interest was further amplified when CNBC’s Jim Cramer described SELLAS as “a great spec,” underscoring how imminent REGAL data and the progress of second AML candidate SLS009 are shaping perceptions of the company’s pipeline. We’ll now examine how the approaching REGAL...
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout
CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."